clinical trial · NCT05019521
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Alexion Pharmaceuticals, Inc.·phase2·terminated·n = 365
Geographic AtrophyDanicopanPlacebo
brief summary
This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.
started
Aug 23, 2021
primary completion
Jul 5, 2024
completion
Jan 21, 2025
last updated
Sep 5, 2025
official title
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol